Previous Close | 18.54 |
Open | 18.30 |
Bid | 18.51 x 100 |
Ask | 18.56 x 100 |
Day's Range | 18.30 - 18.60 |
52 Week Range | 4.18 - 19.50 |
Volume | |
Avg. Volume | 432,672 |
Market Cap | 2.799B |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.50 |
Earnings Date | Aug 07, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.50 |
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.